More evidence needed on Lilly’s weight loss drug, UK watchdog says
(Reuters) – UK’s drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly’s weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) in its draft guidance said it asked the company for …
More evidence needed on Lilly’s weight loss drug, UK watchdog says Read More »









